Horizon Therapeutics (HZNP) Tops Q3 EPS by 19c; Raises Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Stifel Reiterates Buy Rating on Horizon Therapeutics (HZNP) Following Results
November 2, 2022 11:51 AM EDTStifel analyst Annabel Samimy reiterated a Buy rating and $138.00 price target on Horizon Therapeutics (NASDAQ: HZNP) as results showed Tepezza sales are on the mends, with peak guidance raised.
The analyst commented, "Coming off a challenging 1H22 Tepezza transitionary period, HZNP returned to solid performance, reporting revenues... More
